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Coculture of bovine cartilage with
synovium and fibrous joint capsule
increases aggrecanase and matrix
metalloproteinase activity
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Abstract
Background: A hallmark of osteoarthritis is increased proteolytic cleavage of aggrecan. Cross talk between cartilage
and the synovium + joint capsule (SJC) can drive cartilage degradation by activating proteases in both tissues. We
investigated aggrecan proteolysis patterns in cartilage explants using a physiologically relevant explant model of
joint injury combining cartilage mechanical compression and coincubation with SJC.
Methods: Bovine cartilage explants were untreated; coincubated with SJC; or subjected to mechanical injury
and coincubated with SJC, mechanical injury alone, or mechanical injury and incubated with tumor necrosis
factor-α (TNF-α). To compare the patterns of aggrecan proteolysis between 6 h and 16 days, release of sulfated
glycosaminoglycans and specific proteolytic aggrecan fragments into medium or remaining in cartilage
explants was measured by dimethylmethylene blue and Western blot analysis.
Results: Aggrecanase activity toward aggrecan was observed in all conditions, but it was directed toward the
TEGE↓ARGS interglobular domain (IGD) site only when cartilage was coincubated with SJC or TNF-α. Matrix
metalloproteinase (MMP) activity at the aggrecan IGD site (IPES↓FFGV) was not detected when cartilage was
exposed to TNF-α (up to 6 days), but it was in all other conditions. Compared with when bovine cartilage was
left untreated or subjected to mechanical injury alone, additional aggrecan fragment types were released into
medium and proteolysis of aggrecan started at an earlier time when SJC was present.
Conclusions: Indicative of different proteolytic pathways for aggrecan degradation, the SJC increases both
aggrecanase and MMP activity toward aggrecan, whereas TNF-α inhibits MMP activity against the IGD of aggrecan.
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Background
Articular cartilage is a dynamic tissue in synovial joints
that can withstand substantial loads within physiological
levels [1, 2]. Aggrecan, the major proteoglycan of cartil-
age, is substituted with negatively charged sulfated gly-
cosaminoglycans (sGAGs) and forms large aggregates by
binding to hyaluronan [3]. The negative charge density
induces a high osmotic swelling pressure within cartil-
age, restrained by the collagen fibril network [3]. These
osmotic and electrostatic repulsive interactions provide
more than 50% of cartilage’s equilibrium compressive
modulus. In addition, the closely spaced sGAG chains
resist fluid flow caused by dynamic compression quanti-
fied at both the molecular level [4] and the tissue level
[5]. The resulting intratissue pressurization caused by
dynamic compression greatly increases cartilage’s dynamic
modulus at high loading rates. Proteolytic cleavage of
aggrecan is an important feature in osteoarthritis (OA)
[6–8]. Aggrecanase-1 and aggrecanase-2 (a disintegrin and
metalloproteinase with thrombospondin motifs 4 and 5
[ADAMTS4 and ADAMTS5, respectively]) and the matrix
metalloproteinases (MMP-1, MMP-3, MMP-8, MMP-9,
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and MMP-13) are believed to be the most important
enzymes responsible for the proteolytic degradation of
aggrecan [9].
A severe joint injury leads to an increased risk of develop-
ing posttraumatic osteoarthritis (PTOA) [10]. PTOA patho-
genesis is multifactorial, and many risk factors associated
with developing nontraumatic OA, such as age, obesity,
and genetic variation, may also apply to PTOA [10]. With
regard to knee OA, the risk is related to the integrity of the
menisci; to associated compressive injuries to ligaments,
cartilage, and bone; and to joint synovitis [11–14]. In the
acute phase of injury, impact forces applied over the knee
joint in combination with hemarthrosis lead to activation
and recruitment of immune cells to the knee joint, produ-
cing an inflammatory and procatabolic joint environment.
Several reports have demonstrated rapid increases in pro-
and anti-inflammatory cytokines, proteases, and proteolytic
activity after a severe knee injury [15–22]. Cells of the syno-
vium and fibrous joint capsule (referred to hereafter as the
synovium + joint capsule [SJC]), comprising resident in-
flammatory cells, synovial cells, and other cells such as
endothelial cells and blood leukocytes, contribute to joint
inflammation by producing proinflammatory mediators
and proteases such as aggrecanases and MMPs [23, 24].
Matrix molecule fragments and cell debris released into the
joint after trauma lead to activation of various cells in the
cartilage and the SJC, further increasing the proinflamma-
tory response [24]. In the long term, imbalance between
pro- and anticatabolic activities may lead to progressive car-
tilage extracellular matrix degradation and development of
OA [15, 19, 25–29].
In the present in vitro study, we investigated differ-
ences in the preferred enzymatic cleavage of aggrecan in
bovine cartilage explants cocultured with or without
SJC, cartilage exposed to mechanical trauma, or cartilage
exposed to exogenous tumor necrosis factor-α (TNF-α).
We hypothesized that in this coculture system, there is
cross talk between traumatized cartilage and the SJC
through cell- and matrix-derived factors, leading to in-
creased aggrecanase and MMP cleavage of the cartilage
aggrecan. To quantify aggrecanase and/or MMP activity
toward aggrecan in these different conditions, we used a
set of well-characterized antibodies directed at different
cleavage sites in the aggrecan molecule.
Methods
Bovine cartilage and SJC harvesting
The methods of cartilage explant acquisition for the ex-
periment are described elsewhere [30]. In brief, articular
cartilage discs were harvested from the femoropatellar
grooves of 1- to 2-week-old calves obtained on the day
of slaughter (Research 87, Boylston, MA, USA). Full-
thickness cartilage cylinders were cored using a 3-mm
dermal punch, and the top 1-mm disc containing an in-
tact superficial zone was harvested with a blade. Discs
were preincubated in serum-free medium (low-glucose
DMEM [1 g/L]) supplemented with 10 mM HEPES buf-
fer, 0.1 mM nonessential amino acids, 0.4 mM proline,
20 μg/ml ascorbic acid, 100 U/ml penicillin G, 100 μg/
ml streptomycin, and 0.25 μg/ml amphotericin B for 2–3
days (5% CO2, 37 °C). Full-thickness explant discs inclu-
sive of the fibrous joint capsule and the synovium were
harvested [26] from the same animals’ knees using a 5-
mm dermal punch and were preincubated separately in
serum-free medium for 2–3 days. The tissue consisted
of the fibrous joint capsule with a single layer of syno-
vium varying in thickness from 0.5 to 3 mm [31].
Cartilage injury and treatment conditions
After preequilibration, six cartilage discs per condition
were treated according to one of the following condi-
tions: (A) untreated (uninjured cartilage), (B) mechanic-
ally injured (injured cartilage), (C) coincubated with SJC
(uninjured cartilage + SJC), (D) mechanically injured and
coincubated with SJC (injured cartilage + SJC), or (E)
mechanically injured and incubated with exogenous
TNF-α at 25 ng/ml (injured + TNF-α), and (F) six SJC
explants were also cultured alone (SJC alone) [32]. Tissues
and medium were removed from culture at different incu-
bation times ranging from 6 h to 16 days (Table 1). Ex-
plant and SJC samples were harvested from six joints of
three animals. One cartilage explant from one joint of one
animal was cultured alone (conditions A, B, and E) or in
Table 1 Culture conditions A–F and harvesting time after incubation start
Conditions Sample collection, days of incubation
Medium Tissue
Uninjured cartilage (A) 0.25, 1, 2, 4, 6, 8, 10, 12, 14, 16 0.25, 1, 2, 4, 6, 16
Injured cartilage (B) 0.25, 1, 2, 4, 6, 8, 10, 12, 14, 16 0.25, 1, 2, 4, 6, 16
Uninjured cartilage + SJC (C) 0.25, 1, 2, 4, 6, 8, 10, 12, 14, 16 0.25, 1, 2, 4, 6, 16
Injured cartilage + SJC (D) 0.25, 1, 2, 4, 6, 8, 10, 12, 14, 16 0.25, 1, 2, 4, 6, 16
Injured cartilage + TNF-α (E) 0.25, 1, 2, 4, 6 6
SJC alone (F) 0.25, 1, 2, 4, 6, 8, 10, 12, 14, 16 16
Abbreviations: SJC Synovium + joint capsule, TNF-α Tumor necrosis factor-α
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the same well as an SJC explant from the same joint (con-
ditions C and D). In condition F, separate SJC specimens
of were cultured. There were 6 cartilage explants used for
each time point, giving us 36 cartilage explants for the 6
time points in each condition (A–D) plus separate speci-
mens for SJC (conditions C and D). In conditions E and F,
six explants were cultured for 6 and 16 days, respectively.
Medium was changed (300 μl) after 6 h and 2 days of
incubation and thereafter every 2 days until the end of
incubation (Table 1).
In conditions involving mechanical injury, injurious
unconfined compression to a final strain of 50% at a
strain rate of 100%/second was applied to the cartilage
(conditions B and D) using a custom-designed loading
apparatus just prior to the start of culture [30, 33]. Puri-
fied bovine aggrecan (A1D1 fraction, see below) was in-
cubated (0.22 μg sGAG/μl) at 37 °C in serum-free
medium for 1 h or 24 h in the presence or absence of
bovine SJC (67 μg wet wt/μl) and TNF-α (10 pg/ml).
After incubation, the aggrecan solution and tissue were
frozen separately.
Purification of proteoglycans and aggrecan
Proteoglycans (including full-length aggrecan and pro-
teolytic fragments of aggrecan) were purified by guan-
idine extraction from all cartilage discs and SJCs. The
discs (approximately 10 mg each) were extracted by
stirring at 4 °C in a total of 17 μl of extraction buffer
(50 mM Na+-acetate, 4 M guanidinium HCl, 10 mM
ethylenediaminetetraacetic acid [EDTA], 100 mM 6-
aminocaproic acid, 10 mM N-ethylmaleimide, 5 mM
benzamidine HCl, 1 mM phenylmethanesulfonyl fluoride,
pH 6) per milligram of tissue. Thereafter, the guanidine-
extracted proteoglycan sample was centrifuged (20,000 × g,
20 minutes at 4 °C) to collect the supernatant, which was
precipitated for 1 h at −20 °C with 5 vol of ice-cold acetone.
The proteoglycan pellets were then collected by centrifuga-
tion (20,000 × g, 20 minutes at 4 °C) and dissolved in degly-
cosylation buffer (50 mM Tris-acetate, 50 mM Na+-acetate,
10 mM EDTA, pH 7.6). In separate tests, aggrecan was
purified from freshly harvested, untreated bovine calf
femoropatellar groove cartilage samples that were immedi-
ately frozen after removal from the same knee joints as the
treated cartilage explants. Briefly, proteoglycans were first
purified by guanidine extraction (as described above), and
aggrecan was then purified by CsCl density centrifugation
to collect the A1D1 fraction [34].
Analysis of sGAG and aggrecan
Culture medium, guanidine-extracted proteoglycan samples
from cartilage, and SJCs were analyzed for sGAG content
using 1,9-dimethylmethylene blue (DMMB) [35], with the
following changes: 20-μl samples or standards (chondroitin
sulfate [CS], catalogue number C4384; Sigma-Aldrich, St.
Louis, MO, USA) were mixed on a 96-well microtiter plate
with 200 μl of DMMB, and absorbance was measured at
520 nm with a plate reader.
For Western blot analysis, samples were deglycosylated
as described elsewhere [8], with the exception that in-
cubation was performed with lower keratanase II con-
centrations but for a longer time with chondroitinase
ABC (EC 4.2.2.4, 2 h at 37 °C, 1 mU/mg sGAG; Sigma-
Aldrich), keratanase (EC 3.2.1.103, 1 h at 37 °C, 1 mU/
mg sGAG; Seikagaku, Tokyo, Japan), and keratanase II
(Bacillus sp. Ks36, 3 h at 37 °C, 0.01 mU/mg sGAG;
Seikagaku). Deglycosylated samples were precipitated
with 5 vol of ice-cold acetone, and proteins were col-
lected by centrifugation (20,000 × g, 20 minutes at 4 °C)
and dissolved in 40–50 μl of 2× concentrated sample
buffer (SB) (NuPAGE Novex; Life Technologies, Carlsbad,
CA, USA) in the following conditions: 4 μl of medium/1
μl of SB, 10–150 μg wet wt cartilage/1 μl of SB, and 80–
200 μg wet wt SJC/1 μl of SB.
For quantitative Western blotting of aggrecan frag-
ments, purified calf cartilage aggrecan A1D1 fraction (8
standard points per gel; 0.02–0.48 μg of sGAG loaded per
well) was used as the standard for aggrecan G3 fragments
[36]. Calf cartilage aggrecan A1D1 fraction (500 μg) was
digested for 24 h by ADAMTS4 (0.5 μg) [37] (6 standard
points per gel; 0.01–0.36 μg of sGAG loaded per well) and
was used as the standard for ARGS-aggrecan fragments.
Calf cartilage aggrecan A1D1 fraction (100 μg) was
digested for 24 h by MMP-3 (1 μg) [38] (7 standard points
per gel [0.002–0.018 μg of sGAG loaded per well]) and
was used as the standard for FFGV-aggrecan fragments.
Because KEEE standards were not available, calf cartilage
aggrecan A1D1 fraction (80 μg) was digested 10 minutes
with ADAMTS4 (0.08 μg) for use as a control sample (1
μg of sGAG loaded per well three times) for quantification
of KEEE fragments, expressing the data as arbitrary units
of the control sample. All standards were deglycosylated.
FFGV, ARGS, KEEE, and G3 aggrecan fragments were
quantified by Western blot analysis (using the LAS-1000
imaging system and Image Gauge version 3.2 software
[FUJIFILM Medical Systems, Stamford, CT, USA], with
settings of regions of interest done by one experienced op-
erator [MH]) in medium samples (i.e., six samples per
time point and condition). On the basis of the film images
of these experiments, an experienced operator (AS) deter-
mined the presence and absence of bands and the time
point when a band was first observed.
Immunoreactions were done [34] using anti-ARGS
(neoepitope monoclonal OA-1 antibody, 5.3–14 μg/ml;
GlaxoSmithKline), anti-AGEG (neoepitope sera, 1:500;
GlaxoSmithKline), anti-FFGV (neoepitope monoclonal AF-
28 antibody, 0.5 μg/ml; EMD Millipore, Billerica, MA,
USA), anti-G3 (polyclonal antibody, 5 μg/ml, PA1-1745;
Pierce Biotechnology, Rockford, IL, USA), anti-KEEE
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(neoepitope sera, 1:1000), anti-LGQR (neoepitope
sera, 1:500), anti-ARLE (neoepitope sera, 1:2000), anti-
G1 (sera, 1:5000) against G1 sequence ATEGQVRVN-
SIYQDKVSL, together with secondary peroxidase-
conjugated antibodies of horse antimouse immuno-
globulin G (IgG) (1:10,000–1:25,000, catalogue number
7076; Cell Signaling Technology, Danvers, MA, USA) and
goat antirabbit IgG (20 ng/ml, catalogue number 074-
1516; Kirkegaard & Perry Laboratories, Gaithersburg, MD,
USA). The immunobands were visualized using ECL 2
Western Blotting substrate (Pierce Biotechnology) to-
gether with a luminescence image analyzer (LAS-1000)
and film (Amersham Hyperfilm ECL; GE Healthcare Life
Sciences, Little Chalfont, UK). Western blotting was done
to verify immunoband blocking of antibody reactions [36].
All the bovine aggrecan fragments detected by Western
blot analysis in the medium and cartilage plugs in this
study are described in Additional file 1 and are illustrated
(Fig. 1 and Additional file 1: Figure S1).
Statistics
The ratios of FFGV, ARGS, G1-KEEE, and G1–G3 frag-
ments in medium to the total amount of aggrecan
(sGAG left in the cartilage explant plus sGAG released
into the medium during the 16 days of culture) in the
explant system were calculated. The total amount of
sGAG released into the medium was calculated as the
cumulative amount of sGAG detected in the medium
changed every 2 days over the 16 days of incubation. Be-
cause of the low number of animals (n = 3 cows), a nor-
mal distribution was assumed but not tested. All tests
were performed using the paired-samples Student’s t test
of statistical significance (IBM SPSS Statistics version 20
software; IBM, Armonk, NY, USA). A P value <0.05 was
considered statistically significant. The number of ani-
mals used in the statistical analysis was 3, where n = 1
was defined as the mean amount of aggrecan fragment
from two cartilage explants (one from each separate
knee joint) of the same cow. This approach accounts for
intra- and interanimal variability. When the quantified
amount was below the limit of detection, it was set to
half the lowest standard point before statistical testing.
Results
Aggrecan left in cartilage or released into medium
We used sGAG as a measure of total aggrecan content.
The amount of sGAG extracted from the SJC or released
into medium from SJC explants was very low: approxi-
mately 200-fold less than cartilage explants (Fig. 2a).
Hence, the contribution of aggrecan from the SJC to the
Fig. 1 Matrix metalloproteinase (MMP) and aggrecanase cleavage sites in bovine aggrecan. Aggrecanase and MMP cleavage sites of bovine
aggrecan were identified by amino acid sequence comparison with human aggrecan sequence by Western blot analysis of bovine aggrecan (see
Additional file 1: Figure S1) and as previously described [38, 47, 54–56]. Bovine aggrecan fragments, with molecular mass in kilodaltons in brackets,
detected in explant cultures are shown. Using GVEDI(L)SG(R/V)L as a consensus sequence for MMP digestion resulted in 14 potential cleavage sites for
MMP in the bovine CS1 region. The amino acid numberings are based on the full-length bovine aggrecan amino acid sequence starting
with the N-terminal 1MTTL and finishing with the C-terminal STAH2364 (National Center for Biotechnology Information accession number
P13608). IGD Interglobular domain, KS Keratan sulfate region, CS Chondroitin sulfate region, G1–G3, Globular domains 1–3
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explant system was considered negligible in the present
study.
The total amount of sGAG (sum of what was left in
cartilage and released into the medium) increased from
6 h to day 16 in conditions A (uninjured cartilage; 1.7-
fold), B (injured cartilage; 1.6-fold), and C (uninjured
cartilage + SJC; 1.4-fold), but not in condition D (injured
cartilage + SJC; 0.95-fold) (Fig. 2a), suggesting de novo
synthesis of aggrecan in conditions A–C during the cul-
ture period. However, full-length G1–G3 aggrecan present
in the cartilage, quantified by Western blot analysis, de-
creased by between 57% and 66% from 6 h to day 16 in all
conditions (data not shown). This suggests that a substan-
tial fraction of full-length aggrecan present at the start of
the experiment was either released from the cartilage or
C-terminally truncated, thus missing the G3 domain.
The accumulated release of sGAG into medium over the
16 days of incubation was similar in conditions A–D (with
or without injury, with or without SJC). After 6 days of cul-
ture, the release of sGAG into medium was approximately
a
b
Fig. 2 Amount of sulfated glycosaminoglycan (sGAG) in cartilage and medium during explant culturing. a Total amount of sGAG in the explant
system; cartilage and medium combined over 16 days of incubation. b The accumulated amount of sGAG released into medium during the 16
days of culture. The cartilage and synovium + joint capsule (SJC) explants (n = 3) were cultured for from 6 h to 16 days. Number of days of
culture and sGAG amounts (in mean and SD) are presented. T, TNF-α Tumor necrosis factor-α
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50 μg in conditions A–D, whereas the corresponding
amount for condition E (injured cartilage + TNF-α) was
substantially higher at about 270 μg (P ≤ 0.022 for all)
(Fig. 2b). In summary, culture of cartilage explants over
16 days was associated with de novo aggrecan production,
except for conditions where cartilage was mechanically in-
jured and cultured in the presence of SJC.
Enzymatically cleaved aggrecan fragments detected in
medium
Although total amounts of bovine aggrecan released
from the cartilage into the medium (approximated as
total sGAG) did not differ between the culture conditions
A–D (Fig. 2b), analysis of the time-dependent release of
bovine aggrecan fragments revealed striking differences
between these conditions (Table 2 and Additional file 2:
Figure S2). Aggrecan fragments with different proteolytic
cleavage sites were generated and released into the
medium when the cartilage was coincubated with SJC (i.e.,
18 fragments in condition C and 19 fragments in con-
dition D compared with without SJC [A and B] with 12
fragments in each condition) (Table 2). For example,
aggrecanase-generated ARGS and ARLE-G3 fragments
were observed only in medium from culture conditions
in which SJC was present or when exogenous TNF-α
was added (E). MMP-generated FFGV fragments were
observed in all culture conditions, except when exogen-
ous TNF-α was added (E) (Table 2 and Additional file
2: Figure S2). Conditions in which injury was applied to
cartilage (B and D) did not generate different types of
aggrecan fragments compared with conditions without
applied injury (A vs. B and C vs. D).
Together, these results suggest that coincubation with
SJC generates an increased number of different types of
Table 2 Aggrecan fragments detected by Western blot analysis of bovine explant cultures
1) A = uninjured cartilage; B = injured cartilage; C = uninjured cartilage + synovium-joint capsule; D = injured cartilage + synovium-joint capsule; E = injured cartilage + TNF-α;
F = synovium-joint capsule
White to black graded boxes = time periods in days when aggrecan fragments were first observed in medium:
Yellow boxes = detected aggrecan fragments without information when fragments were first observed:
Boxes marked with a straight line ‘—’ = aggrecan fragments not detected
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aggrecan fragments compared with conditions without
SJCs and that cartilage injury does not increase the
number of different aggrecan fragments.
Initiation and preferred order of enzymatic aggrecan
cleavage
Compared with culture conditions without SJC (A and
B), cartilage cultured in the presence of SJC (C and D)
showed a more rapid aggrecan degradation, observed as
an earlier release of several types of aggrecan fragments
into the medium (Table 2). No clear differences in the
initiation or the preferred order of cleavage of aggrecan
were detected between untreated and mechanically in-
jured cartilage (A and B). For all explant conditions, ex-
cept when injured cartilage was cultured in the presence
of TNF-α (E), the earliest aggrecan cleavage was found
at the aggrecanase sites GELE↓GRGT and KEEE↓GLGS
in the CS2 region, based on analysis of the GRGT-KEEE
and G1-KEEE fragments, and at the MMP site
IPES↓FFGV in the interglobular domain (IGD), based on
analysis of the FFGV-G3 fragment. Cuts at these sites
were observed 6 h to 1 day after the start of the
incubation (Table 2). Early aggrecan digestion (6 h to 2
days) was also observed for the MMP cuts in the CS1 re-
gion (based on analysis of the CS1-KEEE fragments). The
cleavage of aggrecan at the aggrecanase site TEGE↓ARGS
in the IGD was detected much later, after 6–8 days of in-
cubation (C and D). Together, these results suggest that in
these explant systems, aggrecan degradation starts earlier
in time in the presence of SJC, and the most preferred
cleavage sites are the aggrecanase sites in the CS2 regions
and the MMP site in the IGD, whereas the least preferred
cleavage site is the aggrecanase site in the IGD.
Quantitative analyses of aggrecanase- and MMP-generated
aggrecan fragments in medium
After 16 days of culture, the mean accumulated release
of FFGV into medium was higher from injured cartilage
(B, 1.4-fold) and from injured cartilage cocultured with
SJC (D, 4.6-fold) than from uninjured cartilage (A)
(Table 3, Fig. 3). The mean accumulated release of
ARGS was 4.8-fold higher from injured cartilage cocul-
tured with SJC than the release from uninjured cartilage
(D vs. A) and 4.6-fold higher than the release from
Table 3 Mean (SD) cumulative levels of aggrecan fragments detected in medium after 16 days of culture
FFGV (ng/μg sGAG) Condition A Condition B Condition C Condition D
0.326 (0.016) 0.447 (0.036) 1.002 (0.359) 1.506 (0.359)
P value Norm
B vs A 0.021 1.37 P value Norm
C vs A 0.428 3.07 C vs B 0.509 2.24 P value Norm
D vs A 0.049 4.62 D vs B 0.067 3.37 D vs C 0.744 1.50
ARGS-CS2 (ng/μg sGAG) Condition A Condition B Condition C Condition D
0.48 (0.036) 0.51 (0.056) 2.10 (1.608) 2.32 (1.134)
P value Norm
B vs A 0.193 1.06 P value Norm
C vs A 0.254 4.38 C vs B 0.255 4.12 P value Norm
D vs A 0.032 4.83 D vs B 0.033 4.55 D vs C 0.850 1.10
G1-KEEE (AU/mg sGAG) Condition A Condition B Condition C Condition D
0.909 (0.604) 0.986 (1.028) 9.297 (0.781) 25.118 (13.842)
P value Norm
B vs A 0.905 1.08 P value Norm
C vs A 0.011 10.23 C vs B 0.016 9.43 P value Norm
D vs A 0.119 27.63 D vs B 0.106 25.47 D vs C 0.298 2.70
G1–G3 (ng/μg sGAG) Condition A Condition B Condition C Condition D
15.3 (2.75) 23.6 (18.27) 9.8 (1.51) 18.6 (14.59)
P value Norm
B vs A 0.460 1.54 P value Norm
C vs A 0.159 0.64 C vs B 0.351 0.42 P value Norm
D vs A 0.935 1.22 D vs B 0.199 0.79 D vs C 0.603 1.90
Abbreviations: FFGV Total levels of FFGV fragments, Norm Normalizing mean values. Conditions: A Uninjured cartilage, B Injured cartilage, C Uninjured cartilage +
synovium + joint capsule, D Injured cartilage + synovium + joint capsule
Statistical (using paired samples t test) significance (P < 0.05) or trends (P < 0.1) are shown in bold
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injured cartilage (D vs. B) (Table 3, Fig. 3b). Owing to
large variations in ARGS concentrations between the
cartilage plugs (Additional file 3: Table S1), no statisti-
cally significant differences were observed between
uninjured cartilage cocultured with SJC (C) and condi-
tions A and B (Table 3), even though visual differences
were observed on the Western blots (Fig. 3b, Additional
file 2: Figure S2). The mean accumulated release of
G1-KEEE was higher in conditions C (9- and 10-fold)
and D (28- and 25-fold) than in condition A and condi-
tion B (Table 3, Fig. 3c). There were no statistically
significant differences in the mean accumulated release of
G1–G3 between any of the conditions (Table 3, Fig. 3d).
These results together suggest that increased levels of
aggrecanase-generated ARGS and KEEE fragments, as
well as MMP-generated FFGV fragments, are released
into medium when cartilage is coincubated with SJC
compared with when SJC is absent. An increased release
of MMP-generated FFGV fragments into medium was
also observed when cartilage was mechanically injured
compared with when cartilage was left untreated.
The SJC produces active aggrecanases and MMPs
Incubation of purified bovine aggrecan with bovine SJC
for 1 h induced aggrecan cleavage at the MMP site
IPES↓FFGV in the IGD, seen as an FFGV-G3 fragment
(Fig. 4a), and cleavage at the aggrecanase site GELE↓GRGT
in the CS2 region, seen as a weak GRGT-G3 fragment
(Fig. 4c). Incubation for 24 h further processed the
FFGV-G3 to a FFGV-CS2 fragment (Fig. 4a), induced
cleavage at the aggrecanase site TEGE↓ARGS in the
IGD, seen as ARGS-CS1/CS2 fragments (Fig. 4b), and
further induced aggrecanase cleavage in the CS2 region,
generating AGEG-G3, LGQR-G3, and ARLE-G3 frag-
ments (Fig. 4c). Addition of TNF-α to these incubations
increased the aggrecanase activity, seen either as faster
a c
b d
Fig. 3 Time-dependent release of aggrecan fragments. The mean accumulated amount of total FFGV (a), ARGS-CS2 (b), G1-KEEE (c), and G1–G3 (d)
quantified by Western blot analysis in medium over 16 days of incubation. Open circles, uninjured cartilage; filled circles, mechanically injured cartilage;
open squares, uninjured cartilage cocultured with synovium + joint capsule (SJC); filled squares, mechanically injured cartilage coincubated with SJC.
For clarity, no error bars are shown; instead, the individual values are shown in Additional file 3: Table S1 sGAG Sulfated glycosaminoglycan
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generation of fragments (AGEG-G3 and LGQR-G3)
(Fig. 4c) or as more intense immunobands (ARGS-CS1/
CS2 and GRGT-G3) (Fig. 4b and c). This increase in pro-
tease activity was not observed for MMP activity (Fig. 4a).
These results suggest that the SJC produces both active
aggrecanases and MMPs and that addition of TNF-α in-
creases the induction of aggrecanases.
Discussion
Proteolysis of human aggrecan showing the fragmentology
of aggrecan has been described previously [8, 9, 34, 38],
but details such as those in this study, showing aggrecan
fragments present in cartilage and released into medium,
have not been described to date, to our knowledge. Our
findings suggest that coincubation of cartilage with SJC
leads to increased proteolytic activity of both MMPs and
aggrecanases against aggrecan. These quantitative findings
were supported by the qualitative analysis of aggrecan
fragments in medium, showing that conditions where
the SJC was present were associated with additional
enzymatically cleaved aggrecan fragment types released
into medium and that proteolytic cleavage of aggrecan
started earlier in time in these conditions. Mechanical
injury of cartilage alone was associated with a small
increase in the amount of FFGV fragments released into
the medium, suggesting increased MMP activity toward
aggrecan compared with the uninjured control.
Whereas high aggrecanase activity against the IGD
cleavage site, as seen by Western blotting, was observed
in cartilage stimulated by mechanical injury + TNF-α, no
MMP activity against the IGD was observed in this con-
dition during the 6 days of culture. This novel finding
suggests that the activated proteolytic pathways are dif-
ferent between the TNF-α-stimulated cartilage and when
cartilage is cultured alone, mechanically traumatized, or
coincubated with SJC.
Activation of inflammatory pathways may be involved
in the pathogenesis of OA and has been shown to asso-
ciate with pain and to be prognostic of OA progression
[14, 39]. As this study and others have shown, the syn-
ovial cells and/or other cells of the fibrous joint capsule
may induce aggrecan cleavage by producing proteases
themselves and could, by producing inflammatory medi-
ators, induce chondrocytes to produce aggrecanases and
MMPs [23, 26]. In the sequelae of severe joint injury,
the activation of Toll-like receptors (TLRs) by matrix
fragments may induce a vicious cycle by downstream ac-
tivation of inflammation pathways [40, 41]. Aggrecan
fragments may also contribute to continued activation of
inflammatory pathways, and a 32-mer aggrecan peptide
was recently shown to have antianabolic, procatabolic,
and proinflammatory bioactivity mediated through TLR2
and nuclear factor-κB [42]. Importantly, with regard to
the findings of the present study, cells other than synovio-
cytes (leukocytes, macrophages, fibroblasts, and endothe-
lial cells) reside in the matrix underlying the synovial
lining and could contribute to increased protease activity
in the cartilage explant in vitro system [43, 44].
Our results extend previous findings suggesting that
cross talk between cartilage and SJC could increase
aggrecanase activity in the cartilage [23, 45] by showing
that coincubation of mechanically injured cartilage with
SJC increases both MMP and aggrecanase activity. We
also found that the SJC produces active aggrecanases
a b c
Fig. 4 Incubation of aggrecan with synovium + joint capsule (SJC). Bovine aggrecan A1D1 fraction (purified from cartilage) was incubated for 1 h
or 24 h with or without bovine SJC in the presence or absence of externally added tumor necrosis factor-α (TNF-α) (see Methods section of main text).
After incubation, the SJC was removed and aggrecan samples were deglycosylated and run on 3–8% Tris-acetate SDS gels, and immunobands were
visualized by Western blotting using FFGV (a), ARGS (b), and G3 (c) aggrecan antibodies. Bovine aggrecan fragments discussed in the text are shown
on the left side in each panel with the molecular mass indicated in kilodaltons. Representative Western blot images from full-size blotted gels are
shown. Sulfated glycosaminoglycan (sGAG) was loaded at 2–3 μg/lane. *Bands considered to be false-positive immunobands because they could not
be blocked by their corresponding immunopeptides
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and MMPs. Our study further extends previous investi-
gations by showing that the coincubation of cartilage
with SJC induces not only aggrecan cleavage in the IGD
(generating ARGS-CS2 fragments) [45, 46] but also pro-
teolytic cleavage between CS2 and G3 (generating
ARLE-G3 fragments), and leads to a higher degree of
cleavage in the CS2 region (generating G1-KEEE frag-
ments). This is important, considering that aggrecan
degradation in this explant study, and in other in vitro
studies [38, 47], starts with cleavage in the CS region
followed by cleavage in the IGD.
Interestingly, the findings of the present study indicate
that mechanical injury to cartilage alone, previously
shown to induce increased MMP and aggrecanase gene
expression (250-fold and 40-fold, respectively) [25], did
not increase aggrecanase-mediated digestion of aggre-
can. This novel observation suggests that additional sol-
uble factors from the SJC are essential to increasing
aggrecanase degradative activity toward aggrecan in the
cartilage. We also found evidence of more MMP activity
in mechanically injured cartilage with or without coincu-
bation with SJC compared with cartilage cultured alone.
These findings are consistent with previous studies
which have shown that the combination of mechanical
injury of cartilage plus incubation with inflammatory cy-
tokines led to the release of significantly greater amounts
of sGAG and specific mass spectrometry-detected matrix
fragments (e.g., aggrecan, collagen III, cartilage oligomeric
matrix protein) from the cartilage than cytokine treatment
alone [27, 48]. Taken together, the findings of the
present study are consistent with the hypothesis that
mechanical injury alone does not induce or alter the
mechanisms underlying aggrecan proteolysis but can
affect the rate of release of the resulting fragments
from the tissue via altered transport/diffusion. Also,
the increased MMP activity observed in the mechan-
ically injured cartilage coincubated with SJC could be
related to increased access to the cartilage for proin-
flammatory molecules and proteases released from
the SJC [27].
In contrast, when mechanically injured cartilage was
cultured in the presence of TNF-α, only aggrecanase and
no MMP activity was detected. These findings are inter-
esting and could imply that different intracellular path-
ways for inducing aggrecan degradation are activated,
depending on if cartilage is stimulated by SJC or by
TNF-α. Such differences may be crucial when interpret-
ing results from in vitro studies and when assessing the
physiological relevance of any given model.
These findings are furthermore consistent with previ-
ous in vitro and in vivo investigations showing that high
concentrations of catabolic cytokines such as TNF-α
lead to early (8 h to 2 days) aggrecanase activity [49, 50].
In agreement with Madsen et al. [50], who used a similar
bovine explant system, we did not detect MMP-gener-
ated FFGV fragments in the medium or in the cartilage
during the 6 days of cartilage explant culture in the
presence of TNF-α. In all other conditions, FFGV-
aggrecan was detected as early as 1–2 days after incu-
bation started. More complex systems, such as in vivo
lipopolysaccharide-induced joint inflammation or acute
knee injury, have implicated increased MMP activity to-
ward type II collagen within 1 day of insult [15, 20, 51, 52].
However, whether MMP activity toward aggrecan is in-
creased in these conditions is not well understood [53].
Studies designed to identify which factors released from
the SJC increase aggrecanase and MMP activity are war-
ranted. If these factors could be singled out, then they
could represent novel targets for treatment of PTOA or
joint injury.
There are several limitations to the present investigation.
Owing to the small study sample size (three animals), our
findings need to be repeated. Of note, the excision of SJC
before culture traumatizes the SJC tissue, and resident
cells may respond to this injury with an inflammatory
phenotype. This is also applicable to the cartilage. We
must also keep in mind that very young bovine cartilage
was used in the experiment, and we do not know if the
pattern of proteolysis is similar in older bovine cartilage or
in adult human cartilage, even though the aggrecan frag-
ment pattern observed in the bovine medium resembles
the pattern seen in synovial fluid from patients with
OA (Additional file 1: Figure S1). However, using this
young bovine system of very tightly controlled age, we
have previously shown that animal-to-animal variations
in cartilage behavior are typically no larger than speci-
men-to-specimen variations within a single animal, giving
us confidence that the results presented are meaningful. A
strength of the present study is that we were able to follow
a course of events using different experimental conditions,
using well-characterized bovine aggrecan fragments rather
than observing momentary time frames of the joint milieu,
as is the case in analysis of joint fluid after, for example, a
joint injury.
Conclusions
The time-dependent release of bovine aggrecan frag-
ments from cartilage explants during different culture
conditions revealed striking differences related to activa-
tion of different proteolytic pathways by the presence of
SJC or TNF-α. On the whole, our findings are consistent
with the important involvement of the SJC in joint car-
tilage aggrecan cleavage. The SJC may induce aggrecan
cleavage in the mechanically injured cartilage by produ-
cing both aggrecanases and MMPs, whereas exogenous
TNF-α leads to aggrecan cleavage by activating aggre-
canase and inhibiting MMP activity. The cells of the
synovium and fibrous joint capsule may also secrete
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active molecules (e.g., cytokines) that can stimulate
cartilage-originated aggrecanase and MMP activity, impli-
cating that the cartilage coculture system including SJC
may reveal additional physiologically relevant matrix
degradation mechanisms associated with joint injury.
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fragments detected by Western blot analysis. Figure S1 Bovine aggrecan
fragments detected by Western blot analysis. (PDF 353 kb)
Additional file 2: Figure S2. Anti-FFGV (a), anti-ARGS (b), anti-KEEE (c),
and anti-G3 (d) Western blotting of medium samples. (PDF 647 kb)
Additional file 3: Table S1. The amount of aggrecan fragments
released into medium. (PDF 79 kb)
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